Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Invex Therapeutics Ltd. ( (AU:IXC) ).
Invex Therapeutics reported new preclinical findings from its collaboration with Tessara Therapeutics, showing Exenatide improved neuronal cell survival and reduced neurofilament light chain levels and key pro-inflammatory cytokines in Tessara’s ADBrain model, suggesting potential early therapeutic benefits in Alzheimer’s disease. The company has since launched an expanded preclinical program with Tessara to evaluate Exenatide, Dulaglutide and combination regimens in the ADBrain platform, while maintaining a solid cash position of $4.52 million and modest quarterly operating cash outflows, alongside minor corporate changes including its deferred AGM and the resignation of a joint company secretary.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an ASX-listed biopharmaceutical company focused on developing and commercialising Exenatide for neurological conditions associated with raised intracranial pressure. The company is expanding its research footprint into neurodegenerative diseases by testing GLP-1 receptor agonists, including Exenatide and Dulaglutide, in advanced Alzheimer’s disease models.
Average Trading Volume: 26,125
Technical Sentiment Signal: Sell
Current Market Cap: A$7.52M
Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.